Affinity and Efficacy Studies of Tetrahydrocannabinolic Acid A at Cannabinoid Receptor Types One and Two.

biosynthesizes Δ-tetrahydrocannabinolic acid (THCA-A), which decarboxylates into Δ-tetrahydrocannabinol (THC). There is growing interest in the therapeutic use of THCA-A, but its clinical application may be hampered by instability. THCA-A lacks cannabimimetic effects; we hypothesize that it has little binding affinity at cannabinoid receptor 1 (CB). Purity of certified reference standards were tested with high performance liquid chromatography (HPLC). Binding affinity of THCA-A and THC at human (h) CB and hCB was measured in competition binding assays, using transfected HEK cells and [H]CP55,940. Efficacy at hCB and hCB was measured in a cyclic adenosine monophosphase (cAMP) assay, using a Bioluminescence Resonance Energy Transfer (BRET) biosensor. The THCA-A reagent contained 2% THC. THCA-A displayed small but measurable binding at both hCB and hCB, equating to approximate K values of 3.1μM and 12.5μM, respectively. THC showed 62-fold greater affinity at hCB and 125-fold greater affinity at hCB. In efficacy tests, THCA-A (10μM) slightly inhibited forskolin-stimulated cAMP at hCB, suggestive of weak agonist activity, and no measurable efficacy at hCB. The presence of THC in our THCA-A certified standard agrees with decarboxylation kinetics (literature reviewed herein), which indicate contamination with THC is nearly unavoidable. THCA-A binding at 10μM approximated THC binding at 200nM. We therefore suspect some of our THCA-A binding curve was artifact-from its inevitable decarboxylation into THC-and the binding affinity of THCA-A is even weaker than our estimated values. We conclude that THCA-A has little affinity or efficacy at CB or CB.